scholarly journals Detection of relapse in non-Hodgkin's lymphoma: Role of routine follow-up studies

2001 ◽  
Vol 69 (1) ◽  
pp. 41-44 ◽  
Author(s):  
Avishay Elis ◽  
Dorit Blickstein ◽  
Osnat Klein ◽  
Rivka Eliav-Ronen ◽  
Yosef Manor ◽  
...  
Keyword(s):  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
Follow Up Studies

The role of interleukins and the widely studied TNF-α in non-Hodgkin’s lymphoma

2021 ◽  
Vol 38 (5) ◽  
Author(s):  
Kyle P. D’mello ◽  
Lei Zhao ◽  
Erin C. Kaser ◽  
Ziwen Zhu ◽  
Huaping Xiao ◽  
...  
Keyword(s):  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
Tnf Α

Molecular Pathogenesis of Non-Hodgkin's Lymphoma: the Role of Bcl-6

2003 ◽  
Vol 44 (sup3) ◽  
pp. S5-S12 ◽  
Author(s):  
Laura Pasqualucci ◽  
Oxana Bereschenko ◽  
Huifeng Niu ◽  
Ulf Klein ◽  
Katia Basso ◽  
...  
Keyword(s):  
Hodgkin’S Lymphoma ◽  
Molecular Pathogenesis ◽  
Hodgkin's Lymphoma ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

scholarly journals Role of FDG-PET scan in the management of pediatric mature B cell non-Hodgkin’s lymphoma. CCHE experience

2016 ◽  
Vol 28 (2) ◽  
pp. 95-99 ◽  
Author(s):  
Hany Abdel Rahman ◽  
Mohamed Sedky ◽  
Asmaa Hamoda ◽  
Tarek Raafat ◽  
Ayda Youssef ◽  
...  
Keyword(s):  
B Cell ◽  
Fdg Pet ◽  
Hodgkin’S Lymphoma ◽  
Pet Scan ◽  
Hodgkin's Lymphoma ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
Fdg Pet Scan

Non-Hodgkin's lymphoma with cardiac presentation: evaluation and follow-up with echocardiography and MR imaging

1991 ◽  
Vol 12 (3) ◽  
pp. 464-467 ◽  
Author(s):  
J. J. MONSUEZ ◽  
J. FRIJA ◽  
L. HERTZ-PANNIER ◽  
J. M. MICLEA ◽  
J. M. EXTRA ◽  
...  
Keyword(s):  
Mr Imaging ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

scholarly journals Serum CA 125 is of clinical value in the staging and follow-up of patients with non-hodgkin's lymphoma

Cancer ◽  
1998 ◽  
Vol 82 (3) ◽  
pp. 576-582 ◽  
Author(s):  
Mario Lazzarino ◽  
Ester Orlandi ◽  
Catherine Klersy ◽  
Cesare Astori ◽  
Ercole Brusamolino ◽  
...  
Keyword(s):  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Ca 125 ◽  
Clinical Value ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

First-line treatment with Bendamustine plus Rituximab for patients with indolent non-Hodgkin’s lymphoma or Mantle cell lymphoma: Real-world experience.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e19540-e19540
Author(s):  
Rouslan Kotchetkov ◽  
David Susman ◽  
Lauren Gerard ◽  
Erica DiMaria ◽  
Derek Wayne Nay
Keyword(s):  
Adverse Events ◽  
Hodgkin’S Lymphoma ◽  
Cell Lymphoma ◽  
Hodgkin's Lymphoma ◽  
First Line ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
Mantle Cell ◽  
Grade 3

e19540 Background: Bendamustine plus rituximab (B+R) was established as a preferred first line therapy for patients with previously untreated indolent non-Hodgkin’s lymphoma based on the BRIGHT and STIL trials. However, only few reports on efficacy and safety data of this combination in the real-world setting are available to-date. Methods: We conducted a retrospective review of patients who received therapy with standard doses of B+R in our cancer center from June 2013 to January 2021. Patients with indolent non-Hodgkin’s lymphoma (iNHL) and mantle cell lymphoma (MCL) who received more than one cycle of B+R were evaluated. Results: Amongst a total of 201 patients 56% were males and 44% females. Median age at B+R initiation was 72 years (range 34-94). Follicular lymphoma (FL) (50.3%), marginal zone lymphoma (MZL) (19.4%), and lymphoplasmacytic lymphoma (LPL) (14.5%) were the most common iNHL. Stage 3 and 4 diseases represented 19.9% and 68.6% of patients. Extranodal disease was found in 35.8%. The proportion of patients with high risk disease was 48.5% for FL (FLIPI ≥3), 86.6% for LPL (WMISS score ≥2), and 80.5% for MCL (MIPI score ≥6.2). Prior history of secondary malignancy had 23.4% of patients; 11.4% patients had ECOG 3. Most common indications for B+R initiation were bulky symptomatic lymphadenopathy (69.1%), cytopenia (36.8%) and constitutional symptoms (36.8%). Fifty-eight percent of patients had more than one indication for therapy. Median number of B+R cycles delivered was 6 (range: 1-6), median dose of bendamustine was 90 mg/m2 (range 45-90). Full doses of treatment were given in 66.7% of patients, reduced in 33.3% with mean dose 78.3 mg/m2. A total of 50.8% completed 6 cycles with no delays, in 49.2% treatment was delayed (mean delay time 1.8 weeks). Overall response was 94.5%, with 77.6% complete and 16.9% partial remission. Median duration of follow-up was 35 months (range: 4-91). At the end of follow-up, event free survival (EFS) was 77.1% and overall survival (OS) was 79.6%. Six percent of patients relapsed, 8% developed secondary hematological malignancies, including 14 cases of aggressive B-cell lymphoma and 2 cases of MDS. 16.9% of patients required support with G-CSF. Grade 3-4 neutropenia was recorded in 22.4%, febrile neutropenia in 7.5%, grade 3-4 anemia in 7.9%, and grade 3-4 thrombocytopenia in 3.9% of patients. Rituximab-associated infusion reactions, skin rash, thrombophlebitis, and infection were the most common non-hematological adverse events. A total of 80.6% of patients proceeded to rituximab maintenance. Conclusions: B+R chemoimmunotherapy is feasible to administer in non-clinical trial setting. Despite more dose reduction as compared to STIL trial, B+R retained its efficacy with comparable EFS and OS. No new adverse events or increase in secondary malignancies were found.

Sign in / Sign up

Export Citation Format

Share Document